Riboflavin
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Riboflavin: From Vitamin Deficiency Disorder to Biotin Metabolic Disease
One-Sentence Summary
Riboflavin (vitamin B2) is originally used to treat and prevent vitamin deficiency disorders. The TxGNN model predicts it may be useful for biotin metabolic disease, but there are no registered clinical trials and the 20 publications found are mostly general B-vitamin reviews, so the evidence is indirect only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Vitamin deficiency disorder |
| Predicted New Indication | Biotin metabolic disease |
| TxGNN Prediction Score | 94.88% |
| Evidence Level | L4 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not currently available. Based on known information, riboflavin is the precursor of the cofactors FAD and FMN, which flavoenzymes use in mitochondrial energy metabolism. Its efficacy in vitamin deficiency is well established, and mechanistically it may be applicable to related metabolic disorders.
Biotin is also a B-vitamin cofactor, acting for carboxylase enzymes. Both vitamins work in overlapping energy-metabolism pathways. Multi-B-vitamin supplementation is already used in some inborn errors of metabolism, so a link between riboflavin and biotin-related disorders (such as biotinidase or holocarboxylase synthetase deficiency) is plausible.
However, the retrieved literature is general: B-vitamin reviews, a compounded multivitamin capsule paper, and inborn-errors overviews. None shows riboflavin-specific clinical efficacy in biotin metabolic disease. The support is therefore indirect.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Of the 20 publications retrieved, none is an RCT. The most relevant are listed below (reviews and case reports).
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 33158037 | 2020 | Review | Nutrients | B vitamins as enzyme cofactors in metabolism and immune regulation |
| 40076592 | 2025 | Review | Int J Mol Sci | Roles of B vitamins, including B2 and B7, in cancer prevention and progression |
| 41692080 | 2026 | Review | Clin Dermatol | B vitamins in cellular metabolism and dermatology |
| 37189771 | 2023 | Review | Biomedicines | Vitamin B deficiency in diabetic kidney disease |
| 37085971 | 2023 | Case report | J Investig Med High Impact Case Rep | Twin premature infants with riboflavin and biotin deficiency on prolonged parenteral nutrition, with lactic acidosis, rash and multiorgan failure |
| 40258084 | 2025 | Other (compounding) | PLoS One | Stability of thiamine, riboflavin, pyridoxine and biotin capsules prepared in advance for pediatric metabolic diseases |
| 23452774 | 2013 | Review | Rev Neurol | Inborn errors of metabolism in adult neurology; many are treatable |
| 39234898 | 2024 | Review | Clin Pharmacol Ther | Rare diseases linked to vitamin transporter mutations at the blood-brain barrier |
| 7015958 | 1980 | Review | Ann N Y Acad Sci | Interactions among thiamin, riboflavin and other B vitamins |
| 15231238 | 2004 | Review | Ageing Res Rev | Heme synthesis requires riboflavin, biotin and other micronutrients |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN11975P | CERNEVIT FOR INJECTION | Injection, powder, for solution | Not stated in the data compiled for this report |
Safety Considerations
- Contraindications (from knowledge-graph associations, not label text): The knowledge graph links riboflavin to a broad list of conditions, including hypertension, liver failure and liver disease, kidney disease and impaired renal function, epilepsy, peptic ulcer disease, cholestasis, myocardial infarction and coronary artery disease, blood coagulation disease and hemophilia, anxiety disorder, and substance abuse/dependence. These associations may reflect multi-vitamin products and should be verified against the official label.
- Photosensitivity: Riboflavin is a photosensitizer. The only sunburn-related paper retrieved concerns drug-induced photodermatitis, which suggests a possible risk rather than a benefit.
Please refer to the package insert for further safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is high (94.88%), but there are no clinical trials and the literature is indirect: general B-vitamin reviews and one case report of combined riboflavin and biotin deficiency. Nothing shows riboflavin treating biotin metabolic disease. The Singapore product is a multivitamin injection, and no label safety data were available.
To proceed, the following is needed:
- Mechanism of action data, to assess the link between riboflavin and biotin-related pathways
- Package insert warnings and contraindications for the registered product, with the approved indication
- Targeted literature review of riboflavin and biotin supplementation in biotinidase and holocarboxylase synthetase deficiency
- Clarification of the clinical question: whether riboflavin adds benefit beyond biotin itself
- Verification of the knowledge-graph contraindications against label text
Other predicted indications (for reference): None has clinical trial support. Corneal pigmentation (63.66%) has only indirect literature on riboflavin/UVA corneal cross-linking, which is not pigmentation (L4, research question). The others (congenital prothrombin deficiency, type II mixed cryoglobulinemia, ocular tuberculosis, guttate psoriasis, obsolete left bundle branch block, obsolete superimposed infection, valvar pulmonary stenosis, sunburn) rest on model prediction only (L5, Hold).
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.